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Abstract Oligomerization of the short (D2S) and long (D2L)
isoforms of the dopamine D2 receptor was explored in
transfected Cos-7 cells by their C-terminal fusion to either an
enhanced cyan or enhanced yellow fluorescent protein (ECFP or
EYFP) and the fluorescent fusion protein interaction was
monitored by a fluorescence resonance energy transfer (FRET)
assay. The pharmacological properties of the fluorescent fusion
proteins, as measured by both displacement of [3H]nemonapride
binding and agonist-mediated stimulation of [35S]GTPQS binding
upon co-expression with a GKoCys351Ile protein, were not
different from the respective wild-type D2S and D2L receptors.
Co-expression of D2S:ECFP+D2S:EYFP in a 1:1 ratio and
D2L:ECFP+D2L:EYFP in a 27:1 ratio resulted, respectively,
in an increase of 26% and 16% in the EYFP-specific fluorescent
signal. These data are consistent with a close proximity of both
D2S and D2L receptor pairs of fluorescent fusion proteins in the
absence of ligand. The agonist-independent D2S receptor
oligomerization could be attenuated by co-expression with either
a wild-type, non-fluorescent D2S or D2L receptor subtype, but not
with a distinct L2-adrenoceptor. Incubation with the agonist (3)-
norpropylapomorphine dose-dependently (EC50 : 0.23 þ 0.06 nM)
increased the FRET signal for the co-expression of D2S:ECFP
and D2S:EYFP, in support of agonist-dependent D2S receptor
oligomerization. In conclusion, our data strongly suggest the
occurrence of dopamine D2 receptor oligomers in intact Cos-7
cells. ß 2001 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
A growing body of evidence supports the concept that
G protein-coupled receptors (GPCRs) may occur in living
cells as oligomers generated by the association of two or
more molecules of the same GPCR (homo-oligomerization)
or GPCRs belonging to di¡erent families (hetero-oligomeriza-
tion) [1^3]. These include the L2-adrenoceptor [4], muscarinic
m3 receptor [5], vasopressin V2 receptor [6], yeast Ste2 recep-
tor [7], N and U opioid receptors [8,9], thyrotropin-releasing
hormone receptor [10] and chemokine CCR5 receptor [11].
Recent evidence also suggests a requirement of hetero-dimer-
ization between the Q-aminobutyric acid (GABA)B1 and
GABAB2 receptors to generate a functional receptor entity
with di¡erent responses as compared to each receptor which
is non-functional if separately expressed in recombinant mam-
malian systems [12,13]. Earlier experiments on GPCR oligo-
merization have been based on the co-immunoprecipitation of
co-expressed but di¡erently labelled epitope-tagged GPCRs
(see [14]). This approach cannot exclude non-speci¢c GPCR
interactions which may result from either detergent dissolu-
tion of cellular membranes or the use of anti-tag antibodies.
Recent reports [4,9,10,15] successfully applied the resonance
energy transfer between either two £uorescent molecules
(FRET) or one luminescent donor and a £uorescent acceptor
molecule to investigate GPCR homo- and hetero-oligomeriza-
tion.
The D2 class of dopamine receptors (including D2, D3, and
D4 receptors) are GPCRs which couple to the inhibitory Gi=o
heterotrimeric G proteins. The dopamine D2 receptor has two
splice isoforms; the long variant arising from alternative splic-
ing contains a 29 amino acid insertion in its receptor’s third
intracellular loop [16]. Receptors of the D2 class have been
proposed to oligomerize both in vivo and in vitro, based on
the following lines of evidence: (i) a di¡erence in the binding
parameters of labelled benzamide and butyrophenone deriva-
tives led to the hypothesis that [3H]spiperone binds to D2
receptor dimers whereas [3H]raclopride interacts with receptor
monomers [17], and that [3H]raclopride labelled about half the
number of dopamine D2 receptor sites as labelled by
[3H]spiperone [18]. These ¢ndings have been con¢rmed by
photoa⁄nity labelling and competition experiments for inhi-
bition of D2 receptor dimer formation [19] ; (ii) oligomeric D2
and D3 receptor protein associations have been detected in
primate and rodent brain homogenates and in rat GH3 cells
stably expressing a D3 receptor upon immunoprecipitation
and immunoblot experiments [20,21] as well as by a truncated
receptor approach where an N-terminal portion of a D2 re-
ceptor could functionally associate with a C-terminal portion
of a D3 receptor [22] ; (iii) heterodimerization of dopamine D2
receptor and somatostatin receptor 5 (SSTR5), as demon-
strated by a FRET-based assay, yielded an enhanced inhibi-
tion of cAMP production [15] ; and (iv) indirect evidence of
D2 receptor oligomerization has been obtained by the inhibi-
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tion of wild-type D2 receptor function by truncated amino-
and carboxy-terminal D2 receptor portions [23].
In the present study, D2 receptor oligomerization was in-
vestigated by employing a newly developed biophysical meth-
od (see [30]), based on energy transfer from two £uorescently
labelled proteins in close spatial proximity in living cells. D2S
and D2L receptor subtypes were fused to either enhanced cyan
or enhanced yellow £uorescent protein (ECFP, EYFP) and
the interaction of both £uorescent fusion proteins was moni-
tored by the transfer of energy from one to the other. Upon
pharmacological validation of the £uorescent fusion proteins
at the radioligand binding and GK protein activation levels,
the occurrence of D2S and D2L receptor oligomers was con-
¢rmed in both a ligand-independent and agonist-mediated
manner.
2. Materials and methods
2.1. Construction of D2 receptor £uorescent fusion proteins
The stop codon of the D2S and D2L receptor cDNA [24] was modi-
¢ed by PCR to create a unique SmaI restriction site. The entire coding
sequence of either ECFP or EYFP was ligated as a SmaI-NotI frag-
ment in-frame with the modi¢ed D2S or D2L receptor cDNA in a
pCR3.1 expression vector. DNA sequencing of the entire fusion pro-
teins con¢rmed the respective constructions.
2.2. Cell culture and transfection
Cos-7 (ATCC CRL-1651) and CHO-K1 (ATCC CRL-9618) cells
were grown in respectively Dulbecco’s modi¢ed Eagle’s medium and
Ham’s F12 nutrient medium, each supplemented with 10% heat-inac-
tivated fetal calf serum. Radioligand binding and £uorescence assays
were performed in Cos-7 cells, transiently transfected with 10 Wg of
the indicated plasmids (1Wg/Wl) by using a Bio-Rad gene pulser appa-
ratus (5U106 cells, 250 mV, 250 WF). This transient transfection pro-
cedure results in a mixed population of Cos-7 cells either containing
or not the desired plasmid. [35S]GTPQS binding responses were mea-
sured in CHO-K1 cells upon co-transfection with D2S:ECFP,
D2S:EYFP, D2L:ECFP and D2L:EYFP fusion protein plasmids
and GKoCys351Ile protein plasmid [25] using a LipofectAMINE plus
kit under conditions indicated by the supplier. Pertussis toxin (100 ng/
ml) treatment was carried out in complete culture medium for 16 h
before analysis.
2.3. Membrane preparation and radioligand binding assays
Membrane preparations of Cos-7 and CHO-K1 cells were prepared
in 10 mM Tris^HCl, 0.1 mM EDTA, pH 7.5 as previously described
[26]. [3H]Nemonapride (0.1 nM) binding assays were performed on
Cos-7 cellular membranes as described previously [26]. 1 WM of
(+)-butaclamol was added to determine non-speci¢c binding. Ago-
nist-dependent [35S]GTPQS binding responses were performed to the
CHO-K1 membrane preparations described above in 20 mM HEPES,
30 WM GDP, 100 mM NaCl, 3 mM MgCl2, 0.2 mM ascorbic acid
(pH 7.4) under assay conditions described previously [27].
Membrane protein levels were estimated with a dye binding assay
using the Bio-Rad protein assay kit and bovine serum albumin as a
standard [28].
2.4. FRET assay
Cos-7 cells were transiently transfected by electroporation as de-
scribed above with 10 Wg of plasmid encoding either D2S:ECFP or
D2S:EYFP fusion protein alone or both plasmids together, in the
absence or presence of non-£uorescent receptor plasmids as indicated,
or with 9 Wg of D2L:ECFP and 0.33 Wg of D2L:EYFP plasmid, and
seeded in 96 well plates (5U104 cells/well). Fluorescent readings were
performed 24^48 h following transfection using a £uorometric image
plate reader (FLIPR, Molecular Devices). Cells were washed twice
with Hanks’ balanced salt solution (pH 7.4) and were incubated in
100 Wl of this latter bu¡er. The excitation argon laser was set at 457
nm. Emission ¢lters correspond to 445^495 nm to detect ECFP emis-
sion and 500^540 nm to detect EYFP emission. Fluorescent emission
was recorded by a CCD camera for the entire 96 well plate 0.8 s after
excitation and expressed as arbitrary £uorescence units (AFU). When
indicated, ligands were applied to the cells and readings were per-
formed immediately upon treatment. The extinction coe⁄cients (Em,
cm31 M31) are: for ECFP, 26 000 at 433 nm excitation and for
EYFP, 84 000 at 514 nm excitation.
2.5. Statistical analysis
Statistical analysis was performed by a two-group comparison pro-
cedure using Student’s t-test.
2.6. Materials
All molecular biology reagents were from Applied Biosystems (Fos-
ter City, CA, USA), Clontech (Palo Alto, CA, USA) and Invitrogen
(La Jolla, CA, USA). The cell lines were from the American Type Cell
Culture (Rockville, MD, USA). All cell culture reagents were from
Invitrogen Life Technologies (Paisley, UK). [3H]Nemonapride (85 Ci/
mmol) and [35S]GTPQS (1000 Ci/mmol) were, respectively, from New
England Nuclear (Boston, MA, USA) and Amersham Pharmacia Bio-
tech (Les Ulis, France). Dopamine and (3)-norpropylapomorphine
((3)-NPA) were from RBI-Sigma (St. Louis, MO, USA). cis-(+)-
5-Methoxy-1-methyl-2-(di-n-propylamino)tetralin ((+)-UH-232) was
from Tocris (Bristol, UK).
3. Results
3.1. Pharmacological properties of D2 receptor £uorescent
fusion proteins
Cos-7 cells expressed between 8.5 and 15.6 pmol/mg protein
of [3H]nemonapride binding sites when transformed with the
D2S receptor ECFP and EYFP fusion proteins and between
8.5 and 14.9 pmol/mg protein for the D2L receptor ECFP
and EYFP fusion proteins (Table 1). Inhibition of [3H]-
nemonapride binding by a series of dopaminergic ligands in-
cluding the agonists (3)-NPA, bromocriptine, the partial ag-
onist (+)-UH-232 and the putative antagonist nemonapride,
yielded the same inhibition constants for the wild-type D2S,
D2S:ECFP and D2S:EYFP fusion proteins as well as for the
wild-type D2L, D2L:ECFP and D2L:EYFP fusion proteins
(Table 1). We also investigated the ability of these fusion
proteins to activate a recombinant GKoCys351Ile protein by
monitoring [35S]GTPQS binding. In the absence of recombi-
nant GKoCys351Ile protein, neither D2S nor D2L receptors were
able to stimulate [35S]GTPQS binding upon stimulation by
(3)-NPA (10 WM) in CHO-K1 cells (data not shown). The
maximal dopamine (10 WM)-mediated stimulation of
[35S]GTPQS binding as observed with the D2S receptor fusion
proteins was about twice decreased as compared to the wild-
type D2S receptor, but its potency was either not altered for
the D2S:EYFP fusion protein or slightly decreased for the
D2S:ECFP fusion protein. (3)-NPA behaved as an e⁄ca-
cious agonist as compared to dopamine with a potency in
the nanomolar range, slightly decreased for both D2S receptor
fusion proteins as compared to the wild-type D2S receptor
(Table 1). A weak (49^59% stimulation) [35S]GTPQS binding
response was obtained for the wild-type D2L receptor; this
response was decreased (52^65%) at the D2L:ECFP and
D2L:EYFP fusion proteins, therefore agonist dose^response
curves were not performed.
3.2. Oligomerization of D2 receptors
Basal £uorescence emission (445^495 nm) upon laser exci-
tation at 457 nm yielded 1586 þ 112 AFU (n = 8) for Cos-7
cells expressing a D2S:ECFP fusion protein; this value was
similar for Cos-7 cells transfected with either empty plasmid
or plasmid containing a wild-type D2S or D2L receptor or a
D2L:ECFP fusion protein and corresponded to background
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£uorescence. This value was similar with the 500^540 nm ¢lter
set, indicating that this ¢lter set is unable to detect a £uores-
cent ECFP emission. When cells expressed a D2S:EYFP fu-
sion protein, the emitted £uorescence in the 500^540 nm win-
dow increased to 2125 þ 190 AFU (n = 8; Fig. 1), suggesting a
weak excitation of the EYFP £uorochrome in the fusion pro-
tein at 457 nm as expected by the EYFP excitation spectrum
[29]. Co-expression in equivalent plasmid amount of
D2S:ECFP and D2S:EYFP yielded a signi¢cant 26 þ 5%
(n = 15) increase in the emitted £uorescence, suggesting a £uo-
rescence transfer from the laser-excited D2S:ECFP to a
D2S:EYFP in close proximity (less than 100 nm [30]). A
similar experiment with an equimolar amount of D2L:ECFP
and D2L:EYFP did not result in energy transfer. A 27-fold
excess in D2L:ECFP versus D2L:EYFP plasmid yielded a
signi¢cant 16 þ 3% (n = 6) increase in the FRET signal, indi-
cating spatial proximity between the two D2L receptor fusion
proteins. This observed emission was independent of agonist
stimulation. In addition, (3)-NPA dose-dependently increased
the energy transfer to 23 þ 4% (n = 5) above the ligand-inde-
pendent D2S-mediated £uorescence level with a potency of
0.23 þ 0.06 nM (Fig. 2). Dopamine (10 WM) also increased
the FRET signal to 21.5% (20^23%, n = 2). The (3)-NPA
(10 nM)-mediated D2S receptor oligomerization could be in-
hibited by co-treatment with the D2 receptor antagonist
haloperidol (1 WM, Fig. 2). Agonist stimulation of the D2L
Table 1
[3H]Nemonapride and [35S]GTPQS binding responses to either wild-type or dopamine D2S and D2L receptor ECFP and EYFP fusion proteins
[3H]Nemonapride [35S]GTPQS
Cell type Cos-7 CHO-K1




IC50 (nM) Emax (%) EC50 (nM) Emax (%) EC50 (nM)
Receptor/Ligand (3)-NPA Bromocriptine (+)-UH-232 Nemonapride Dopamine Dopamine (3)-NPA (3)-NPA
Wild-type D2S 8.51 þ 0.53 75 þ 13 28 þ 8 120 þ 25 0.72 þ 0.04 141 þ 14 11.8 þ 3.1 132 þ 12 2.7 þ 0.7
D2S:ECFP 9.40 þ 1.25 107 þ 29 40 þ 10 170 þ 6 0.83 þ 0.09 58 þ 10 21.0 þ 1.0 60 þ 9 8.6 þ 0.4
D2S:EYFP 15.6 þ 2.16 96 þ 15 31 þ 6 147 þ 27 0.75 þ 0.07 67 þ 4 14.8 þ 4.6 66 þ 2 5.1 þ 0.8
Wild-type D2L 7.89 þ 1.55 73 þ 18 27 þ 4 123 þ 16 0.67 þ 0.06 49^55 nd 54^59 nd
D2L:ECFP 12.9 þ 2.39 76 þ 24 25 þ 8 132 þ 14 0.90 þ 0.10 19^25 nd 22^28 nd
D2L:EYFP 14.9 þ 2.99 90 þ 18 30 þ 4 113 þ 7 0.84 þ 0.08 17^21 nd 19^23 nd
The wild-type and D2 receptor £uorescent fusion proteins were expressed in Cos-7 or CHO-K1 cells in the co-presence of a recombinant
GKoCys351Ile protein to measure, respectively, [3H]nemonapride (0.10 nM) and [35S]GTPQS (0.5 nM) binding as described in Section 2. Maximal
[35S]GTPQS binding responses (Emax) were expressed as a percentage above the basal [35S]GTPQS binding. Data correspond to the mean or
mean þ S.E.M. of two or four to ¢ve independent transfection experiments, each experimental point being performed in duplicate. nd: not de-
termined.
Fig. 1. Constitutive dopamine D2 receptor oligomerization. Cos-7
cells were transfected with both D2 receptor isoforms (short, S or
long, L) either in their wild-type (WT) form or fused to ECFP or
EYFP £uorescent protein alone or co-expressed, as described in Sec-
tion 2. Molecular ratio were 1:1 for D2S:ECFP+D2S:EYFP plas-
mids and 27:1 for D2L:ECFP+D2L:EYFP plasmids. Fluorescent
readings were performed 0.8 s after laser excitation at 457 nm. Data
correspond to mean þ S.E.M. of six to eight independent transfec-
tion experiments, each experimental point corresponding to the
mean of at least six wells on a culture plate. Statistical analysis was
performed on the AFU using Student’s t-test. *P6 0.05 vs. the £uo-
rescence emitted with D2S:EYFP or D2L:EYFP alone.
Fig. 2. Ligand-dependent dopamine D2S receptor oligomerization.
Cos-7 cells were co-transfected with both D2S:ECFP and
D2S:EYFP fusion proteins as described in Section 2. Fluorescent
readings were performed as described in Fig. 1. Constitutive energy
transfer £uorescence resulting from D2S receptor oligomerization
was 2680 þ 112 AFU. Maximal stimulation as obtained with (3)-
NPA was 3298 þ 136 AFU. Dose^response curve for (3)-NPA (b)
and co-treatment of (3)-NPA (10 nM)+haloperidol (1 WM) (a) are
shown. Data are expressed as a percentage of the maximal stimula-
tion of speci¢c FRET signal (di¡erence in £uorescence between the
co-expression of D2S:ECFP+D2S:EYFP and of D2S:EYFP alone)
obtained with 1 WM (3)-NPA and correspond to mean þ S.E.M. of
three to four independent transfection experiments, each experimen-
tal point corresponding to the mean of at least six wells on a cul-
ture plate.
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receptor £uorescent fusion proteins did not yield an enhance-
ment of the £uorescent signal. Mixture of Cos-7 cells inde-
pendently expressing D2S:ECFP or D2S:EYFP following
transfection did not generate a £uorescent signal (not shown).
The speci¢city of the interaction between D2S:ECFP and
D2S:EYFP was con¢rmed by co-expression of both £uores-
cent fusion proteins with a wild-type, non-£uorescent D2S
receptor. This condition fully abolished the energy transfer
(Fig. 3), in agreement with the formation of D2S:ECFP
plus wild-type D2S and D2S:EYFP plus wild-type D2S oligo-
mers unable to generate a FRET signal. A similar result was
obtained by co-expression with a wild-type D2L receptor. This
suggests indirectly the existence of oligomers involving both
short and long isoforms of the D2 receptor (Fig. 3). Co-ex-
pression of D2S:ECFP and D2S:EYFP with a distinct
L2-adrenoceptor did not modify the £uorescent signal in a
signi¢cant manner (Fig. 3).
4. Discussion
The present report demonstrates that oligomeric forms of
both dopamine D2S and D2L receptors can be obtained by the
association of £uorescently labelled receptors, fused to either
ECFP or EYFP in Cos-7 cells. Such C-terminal £uorescent
fusion proteins yielded a radioligand binding pro¢le similar to
the wild-type, non-£uorescent D2 receptor, indicating that the
fusion process did not modify the global receptor conforma-
tion. Because the intracellular loops of GPCR have been im-
plicated in the interaction with G proteins [31], the fusion of
the 26 kDa ECFP or EYFP portion at the C-terminal end of
the D2 receptor could alter the receptor-dependent G protein
activation. This has been tested upon co-expression of a re-
combinant, pertussis toxin-resistant GKoCys351Ile protein and
monitoring of its activation by the binding of [35S]GTPQS. A
slightly decreased potency and a twice decreased maximal
stimulation for the agonists (3)-NPA and dopamine were
observed for the £uorescent fusion proteins as compared to
the wild-type D2S receptor, suggesting a less e⁄cient GKo pro-
tein coupling. These data indicate that D2S:ECFP,
D2S:EYFP, D2L:ECFP and D2L:EYFP are functional re-
ceptor proteins, they are therefore suitable for use in a
FRET assay. Fluorescence energy transfer has successfully
been applied to demonstrate receptor homo-oligomerization
of various GPCRs including opioid receptors and yeast Ste2
receptor [7,9] and hetero-oligomerization between SSTR5 and
D2 receptors [15]. It has been reported that FRET results in
donor photobleaching due to £uorescent excitation and auto-
£uorescence [32]. In the present study, photobleaching was
not observed during the time course of data recording since
emission was measured less than 1 s after excitation, and for
the entire 96 well plate. We were unable to detect basal £uo-
rescence from the donor protein (ECFP, D2S:ECFP or
D2L:ECFP). This may be due either to the weak £uorescence
intensity of the ECFP molecule [29] or to a phenomenon of
autoquenching, which may also exist for the EYFP-derived
fusion proteins. A low level of auto£uorescence of the accep-
tor EYFP was observed for D2S:EYFP when excitation was
performed at 457 nm. Nevertheless, co-expression of both
D2S:ECFP+D2S:EYFP and D2L:ECFP+D2L:EYFP re-
sulted in respectively a 26% and 16% increase in the signal
emitted in the 500^540 nm ¢lter window as compared to the
D2 receptor EYFP fusion proteins. The detection of a FRET
signal under basal conditions (i.e. in the absence of ligand)
demonstrated a close proximity between the ECFP-labelled
and EYFP-labelled D2 receptor subtypes as the maximum
distance allowing energy transfer between the two £uorescent
proteins is approximately 100 nm [30]. The FRET signal re-
sulting from co-expression of wild-type, non-fused ECFP and
EYFP could not be evaluated in our experimental system
because the £uorescent signal of wild-type EYFP expressed
alone saturated the camera (not shown). Nevertheless, inde-
pendent expression of D2S:ECFP and D2S:EYFP in individ-
ual cells and mixing did not result in a FRET signal, thus
there is no intercellular energy transfer. Thus, the herein ob-
served results can be best explained by the formation of con-
stitutive D2 receptor dimers or oligomers since the FRET
signal could result from dimeric and/or oligomeric D2 recep-
tor complexes. The oligomerization seems more e⁄cient for
the D2S receptor subtype than for the D2L receptor isoform
(Fig. 1).
D2S oligomer formation was also enhanced by agonist acti-
vation, the magnitude of the agonist e¡ect was as important
as the constitutive D2S oligomerization (about 20%). This en-
hancement occurred in a dose-dependent manner, but the po-
tency of (3)-NPA for receptor oligomerization was 10-fold
increased as compared to its potency at wild-type D2S recep-
tors to stimulate [35S]GTPQS binding via a recombinant
GKoCys351Ile protein (see Table 1). Agonist promotion of
FRET could indicate either an increase in the amount of
D2S receptor oligomers and/or a ligand-induced conforma-
tional change in pre-existing D2S receptor oligomers which
results in a closer contact or more favorable orientation of
the ECFP and EYFP portion, thereby increasing the energy
transfer. Ligand-dependent promotion of D2L receptor oligo-
merization could not be observed in our experimental system
and may be linked to the weaker ligand-independent FRET
signal which is observed. Recently, activation of the metabo-
tropic glutamate mGluR1 receptor by glutamate has been
Fig. 3. Inhibition of constitutive D2S:ECFP and D2S:EYFP oligo-
merization. Cos-7 cells were co-transfected with both D2S:ECFP
and D2S:EYFP fusion proteins in either the absence (none) or pres-
ence of plasmid containing wild-type, non-£uorescent D2S or D2L
receptor or L2-adrenoceptor (L2 AR), as described in Section 2.
Fluorescent readings were performed as described in Fig. 1. Data
were expressed as the ligand-independent speci¢c FRET signal, cor-
responding to the di¡erence in £uorescence between the co-expres-
sion of D2S:ECFP+D2S:EYFP and of D2S:EYFP alone. Values
correspond to the mean þ S.E.M. of three independent transfection
experiments, each experimental point corresponding to the mean
of at least six wells on a culture plate. Statistical analysis
was performed on the AFU using Student’s t-test. ***P6 0.001;
NS: Ps 0.05 vs. the £uorescence emitted with both D2S:ECFP+
D2S:EYFP.
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shown to stabilize pre-existing receptor dimers; movements of
the receptor portions involved in dimerization a¡ected the
separation of transmembrane domains and intracellular por-
tions [33]. For other GPCRs, dimerization only occurred in
the presence of agonists like for SSTR5 [15] and gonadotro-
pin-releasing hormone receptor [10].
Competition of £uorescent D2S receptor oligomerization by
wild-type, non-£uorescent receptors was performed to con¢rm
the speci¢city of the receptor interaction. Co-expression of
D2S:ECFP and D2S:EYFP with wild-type D2S receptors
fully abolished the energy transfer, suggesting the formation
of D2S:ECFP+D2S and D2S:EYFP+D2S receptor oligomers.
No competition was obtained with a distinct L2-adrenoceptor,
indicating a speci¢c interaction between D2S receptors. Co-
expression of D2S:ECFP and D2S:EYFP with the D2L recep-
tor subtype also totally abolished the FRET signal. These
data indirectly suggest oligomerization between the short
and long isoforms of the D2 receptor. Nevertheless, these
two receptor subtypes seem to possess a di¡erential compart-
mentalization. Immunohistochemical studies showed that the
D2S receptor predominates in the cell bodies and axons of
dopaminergic neurons of the mesencephalon and hypothala-
mus. On the other hand, the D2L receptor isoform is more
strongly expressed in the striatum and nucleus accumbens
[34]. Oligomerization between D2S and D2L receptor isoforms
is nevertheless not surprising because they only di¡er by a 29
amino acid portion in their third intracellular loop [16]. More-
over, GPCR oligomerization is likely to involve a portion
encompassing the sixth transmembrane domain as shown
for the L2-adrenoceptor [35] and dopamine D1 receptor [36].
Involvement of the C-terminal intracellular portion, which is
directly linked to the £uorescent proteins in the fusion pro-
teins used herein, cannot be excluded.
In conclusion, we applied the energy transfer assay between
two £uorescent proteins to demonstrate dimerization/oligome-
rization of dopamine D2 receptors in both the absence and
presence of agonist. A plausible association between the long
and short isoforms of the D2 receptor cannot be excluded.
The occurrence of GPCR oligomers may be a general phe-
nomenon which constitutes a new challenge in the pharmacol-
ogy of GPCRs.
Acknowledgements: We sincerely thank C. Palmier for advice with the
radioligand binding experiments and S. Brignatz for secretarial assis-
tance.
References
[1] Bouvier, M. (2001) Nature Neurosci. 2, 274^286.
[2] Devi, L.A. (2000) Trends Pharmacol. Sci. 21, 324^326.
[3] Marshall, F.H. (2001) Curr. Opin. Pharmacol. 1, 40^44.
[4] Angers, S., Salahpour, A., Joly, E., Chelsky, D., Dennis, M. and
Bouvier, M. (2000) Proc. Natl. Acad. Sci. USA 97, 3684^3689.
[5] Zeng, F.-Y. and Wess, J. (1999) J. Biol. Chem. 274, 19487^19497.
[6] Schultz, A., Grosse, R., Schultz, G., Guderman, T. and Schone-
berg, T. (2000) J. Biol. Chem. 275, 2381^2389.
[7] Overton, M.C. and Blumer, K.J. (2000) Curr. Biol. 10, 341^344.
[8] Jordan, B.A. and Devi, L.A. (1999) Nature 399, 697^700.
[9] McVey, M., Ramsay, D., Kellett, E., Rees, S., Wilson, S.,
Pope, A.J. and Milligan, G. (2001) J. Biol. Chem. 276, 14092^
14099.
[10] Kroeger, K.M., Hanyaloglu, A.C., Seeber, R.M., Miles, L.E.C.
and Eidne, K.A. (2001) J. Biol. Chem. 276, 12736^12743.
[11] Vila-Coro, A.J., Mellado, M., Martin de Ana, A., Lucas, P., del
Real, G., Martinez, A.C. and Rodriguez-Frade, J.M. (2000)
Proc. Natl. Acad. Sci. USA 97, 3388^3393.
[12] Jones, K.A., Borowsky, B., Tamm, J.A., Craig, D.A., Durkin,
M.M., Dai, M., Yao, W.-J., Johnson, M., Gunwaldsen, C.,
Huang, L.-Y., Tang, C., Shen, Q., Salon, J.A., Morse, K., Laz,
T., Smith, K.E., Hagarathnam, D., Noble, S.A., Branchek, T.A.
and Gerald, C. (1998) Nature 396, 674^679.
[13] White, J.H., Wise, A., Main, M.J., Green, A., Fraser, J., Disney,
G.H., Barnes, A.A., Emson, P., Foord, S.M. and Marshall, F.H.
(1998) Nature 396, 679^682.
[14] Salahpour, A., Angers, S. and Bouvier, M. (2000) Trends Endo-
crinol. Metab. 11, 163^168.
[15] Rocheville, M., Lange, D.C., Kumar, U., Sasi, R., Patel, R.C.
and Patel, Y.C. (2000) J. Biol. Chem. 275, 7862^7869.
[16] Araki, K., Kuwano, R., Morii, K., Hayashi, S., Minoshima, S.,
Shimizu, N., Katagiri, T., Usui, H., Kumanishi, T. and Takaha-
shi, Y. (1992) Neurochem. Int. 21, 91^98.
[17] Armstrong, D. and Strange, P.G. (2001) J. Biol. Chem. in press.
[18] Malmberg, A., Jerning, E. and Mohell, N. (1996) Eur. J. Phar-
macol. 303, 123^128.
[19] Ng, G.Y.K., O’Dowd, B.F., Lee, S.P., Chung, H.T., Brann,
M.R., Seeman, P. and George, S.R. (1996) Biochem. Biophys.
Res. Commun. 227, 200^204.
[20] Nimchinsky, E.A., Hof, P.R., Janssen, W.G.M., Morrison, J.H.
and Schmauss, C. (1997) J. Biol. Chem. 272, 29229^29237.
[21] Zawarynski, P., Tallerico, T., Seeman, P., Lee, S.P., O’Dowd,
B.F. and George, S.R. (1998) FEBS Lett. 441, 383^386.
[22] Scarselli, M., Novi, F., Schallmach, E., Lin, R., Baragli, A.,
Colzi, A., Gri¡on, N., Corsini, G.U., Sokolo¡, P., Levenson,
R., Vogel, Z. and Maggio, R. (2001) J. Biol. Chem. 276,
30308^30314.
[23] Lee, S.P., O’Dowd, B.F., Ng, G.Y.K., Varghese, G., Akil, H.,
Mansour, A., Nguyen, T. and George, S.R. (2000) Mol. Pharma-
col. 58, 120^128.
[24] Pauwels, P.J., Finana, F., Tardif, S., Wurch, T. and Colpaert,
F.C. (2001) J. Pharmacol. Exp. Ther. 297, 133^140.
[25] Dupuis, D.S., Tardif, S., Wurch, T., Colpaert, F.C. and Pauwels,
P.J. (1999) Neuropharmacology 38, 1035^1041.
[26] Pauwels, P.J., Palmier, C., Wurch, T. and Colpaert, F.C. (1996)
Naunyn-Schmiedeberg’s Arch. Pharmacol. 353, 144^156.
[27] Pauwels, P.J., Tardif, S., Palmier, C., Wurch, T. and Colpaert,
F.C. (1997) Neuropharmacology 36, 499^512.
[28] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[29] Miller 3rd, D.M., Desai, N.S., Hardin, D.C., Piston, D.W., Pat-
terson, G.H., Fleenor, J., Xu, S. and Fire, A. (1999) BioTechni-
ques 26, 914^918.
[30] Hovius, R., Vallotton, P., Wohland, T. and Vogel, H. (2000)
Trends Pharmacol. Sci. 21, 266^273.
[31] Bockaert, J. and Pin, J.-P. (1999) EMBO J. 18, 1723^1729.
[32] Xu, Y., Piston, D.W. and Johnson, C.H. (1999) Proc. Natl.
Acad. Sci. USA 96, 151^156.
[33] Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M.,
Kumasaka, T., Nakanishi, S., Jingami, H. and Morikawa, K.
(2000) Nature 407, 971^977.
[34] Khan, Z.U., Mrzljak, L., Gutierrez, A., De la Calle, A. and
Goldman-Rakic, P.S. (1998) Proc. Natl. Acad. Sci. USA 95,
7731^7736.
[35] Hebert, T.E., Mo¡ett, S., Morello, J.-P., Loisel, T.P., Bichet,
D.G., Barret, C. and Bouvier, M. (1996) J. Biol. Chem. 271,
16384^16392.
[36] George, S.R., Fan, T., Xie, Z., Tse, T., Tam, V., Varghese, G.
and O’Dowd, B.F. (2000) J. Biol. Chem. 275, 26128^26135.
FEBS 25364 11-10-01
T. Wurch et al./FEBS Letters 507 (2001) 109^113 113
